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Invasive fungal infections (IFIs) are a common com-
plication in liver transplant recipients. There are no
previous randomized trials of an echinocandin for the
prevention of IFIs in solid organ transplant recipients.
In a randomized, double-blind trial conducted at
University-affiliated transplant centers, 200 high-risk
liver transplant recipients (100 patients per group)
received either anidulafungin or fluconazole for anti-
fungal prophylaxis. Randomization was stratified by
Model for End-Stage Liver Disease score 30 and
receipt of a pretransplant antifungal agent. The
primary end point was IFI in a modified intent-to-treat
analysis. The overall incidence of IFI was similar for the
anidulafungin (5.1%) and the fluconazole groups (8.0%)
(OR 0.61, 95% CI 0.19–1.94, p¼ 0.40). However, anidu-
lafungin prophylaxis was associated with less Asper-
gillus colonization or infection (3% vs. 9%, p¼ 0.08),
lower breakthrough IFIs among patients who had
received pretransplant fluconazole (0% vs. 27%,
p¼ 0.07), and fewer cases of antifungal resistance
(no cases vs. 5 cases). Both drugs were well-tolerated.
Graft rejection, fungal-free survival, and mortality
were similar for both groups. Thus, anidulafungin
and fluconazole have similar efficacy for antifungal
prophylaxis in most liver transplant recipients. Anidu-
lafungin may be beneficial if the patient has an
increased risk for Aspergillus infection or received
fluconazole before transplantation.
Abbreviations: EORTC, European Organization for
Research and Treatment of Cancer; ICU, intensive
care unit; IFI, invasive fungal infection; MELD, Model
for End-Stage Liver Disease; MIC, minimum inhibitory
concentration; M-ITT, modified intent-to-treat; MSG,
Mycoses Study Group
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Introduction
Invasive fungal infections (IFIs) are a significant complica-
tion in organ transplant recipients. Among solid organ
transplant recipients, liver transplant patients have one of
the highest incidences and also the greatest mortality from
fungal infection (1). Consequently, based upon existing
randomized clinical trials (2,3), both the American Society of
Transplantation Infectious Diseases Community of Practice
and the Infectious Disease Society of America clinical
practice guidelines recommend fluconazole for liver trans-
plant recipients at high risk for IFIs (4,5). A survey of liver
transplant programs in North America also found that
fluconazole is themost commonly used agent for antifungal
prophylaxis (6). Potential limitations of fluconazole, howev-
er, include the emergence of fluconazole-resistant non-
albicans Candida species as pathogens, lack of activity for
Aspergillus, and drug interactionswith immunosuppressive
agents leading to adverse events.
The echinocandins have activity for both Aspergillus and
Candida species, including many Candida species resistant
to fluconazole. The echinocandins also have a favorable
safety profile and a low potential for drug interactions.
Similar to the azoles, the echinocandins are both fungicidal
and synergistic in combination with calcineurin-inhibitor
agents for common fungal pathogens (7). In small un-
controlled studies, prophylaxis with caspofungin or mica-
fungin appeared to be well-tolerated in liver transplant
recipients (8–10). Anidulafungin is unique among echino-
candins in that it is eliminated almost exclusively via
biotransformation by nonenzymatic degradation in the
blood without hepatic or renal elimination (11). Therefore,
we conducted the first randomized, double-blind trial of
an echinocandin for antifungal prophylaxis in solid organ
transplant recipients by comparing anidulafungin with
fluconazole for prevention of IFIs in high-risk liver transplant
patients.
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Methods
Study design
This was a randomized, double-blind trial involving liver transplant recipients
at high risk for IFIs conducted between February 2010 and November
2011. The study was approved by the institutional review board at each
participating site.Written informed consentwas obtained from all patients or
their legally authorized representatives.
Patients
Liver transplant patients 18 years of age who had one or more of the
following risk factors for IFI were eligible for the study: retransplantation;
transplantation for fulminant hepatic failure; receipt of corticosteroids for at
least 2 weeks within 4 weeks preceding transplantation; hospitalization for
at least 48 h in the intensive care unit (ICU) at the time of transplantation;
colonization with Candida species at 2 sites within 4 weeks preceding
transplantation; 15U of intraoperative packed red blood cell transfusions
and operative time >6 h; requirement of any form of renal replacement
therapy at the time or within 7 days of transplantation; and reoperation
involving the intraabdominal cavity. These variables as risk factors for IFIs
in liver transplant recipients have been identified in multiple previous
studies (2,12–18). Patients were excluded if they had known hypersensitivi-
ty to the azoles or the echinocandins; had life expectancy of <72 h; or had
received systemic antifungal therapy for an IFI within 4 weeks preceding
transplantation.
Blinding and study drug administration
Eligible patients were randomized 1:1 to receive either anidulafungin or
fluconazole using permuted block randomization. Randomization was
stratified within each center by Model for End-Stage Liver Disease
(MELD) 30 and pretransplant receipt of an antifungal agent within
30 days prior to transplantation. Dosing with the study drug had to
commence within 5 days of transplantation. Anidulafungin was adminis-
tered as a 200mg intravenous loading dose followed by 100mg intravenous
daily. There was no adjustment of the anidulafungin dosage for renal failure.
Fluconazole was administered at a dosage of 400mg intravenously daily.
The fluconazole dosage was adjusted for renal failure as follows: creatinine
clearance <50mL/min and no dialysis (200mg intravenously daily);
continuous renal replacement therapy (400mg intravenously daily); inter-
mittent hemodialysis (400mg intravenously after hemodialysis on dialysis
days and saline infusion without fluconazole on nondialysis days). To
maintain blinding, the study drug was dispensed in identical infusion bags
with the same volume of fluid. Except for the site pharmacists, patients,
research staff, and all members of the clinical team remained masked to
drug assignment throughout the study.
The study drugs were continued for 21 days or until discharge. If a patient
was discharged from the hospital before completion of 21 days of the study
drug, the study drug was discontinued. In patients with ongoing need for
renal replacement therapy, persistent liver allograft dysfunction, continued
ICU stay, or increased immunosuppression for rejection in the previous
21 days, study drug could be continued beyond 21 days for a maximum of
42 days.
Assessments
The primary end point was the incidence of proven or probable IFIs within
90 days of transplantation. IFIs were defined by using the criteria of the
European Organization for Research and Treatment of Cancer/ Mycoses
Study Group (EORTC/MSG) (19). Other assessments included fungal-free
survival, fungal colonization, rejection, graft loss, and all-cause mortality.
Fungal colonization was defined as previously reported in liver transplant
recipients (2). Fungal isolates causing IFIs were tested for in vitro
susceptibility to antifungal agents by a microbroth dilution assay, in
accordance with Clinical Laboratory Standards Institute guidelines (20,21).
Adverse events were recorded until 7 days after the last dose of study drug.
Independent on-site clinical monitoring was conducted for source data
verification and safety assessments. An independent data and safety
monitoring committee provided study oversight.
Statistical analyses
IFIs have been documented in 36–50% of high-risk liver transplant
recipients (14,22–24). Among patients receiving prophylactic fluconazole,
14–23% and an average of 18% developed IFIs (14,22,24). In a non-
comparative study of prophylactic caspofungin in high-risk liver transplant
recipients, 2.8% developed IFIs (8). Thus, assuming an incidence of IFI of
18% in the fluconazole group and 4% in the anidulafungin group, a sample
size of 182 patients (91 patients in each group) would detect the
aforementioned difference with a power of 80% and a¼ 0.05. Adjusting
for a 10%drop out rate, the studywould require a total of 200 patients or 100
patients per study group.
Stata/IC (College Station, TX) was used for statistical analyses. Baseline
characteristics and risk factors were compared using the chi-square test or
rank sum test. The Mantel–Haenszel odds ratio was used to evaluate the
effect of treatment on IFIs in a modified intent-to-treat (M-ITT) population
(randomized patients with no baseline IFI and received>48 h of study drug).
Breakthrough infections, defined as IFIs occurring during receipt of study
drug, were similarly evaluated. The odds of any IFI or only breakthrough IFI in
specific high-risk groups was assessed by the Mantel–Haenszel test.
A Kaplan–Meier estimate was calculated to evaluate the time to IFIs. Fungal-
free survival between the two groups was compared using a log rank test.
Patients who died without evidence of IFI were censured at the date of
death. All remaining patients were censored at day 90 after transplant. The
analysis was repeated using the stratification variables. The Kaplan–Meier
estimate was also used to evaluate all-cause mortality. For this analysis, the
entry point was the day of transplant, and the end point was date of death.
Survivors were censored at day 90 after transplant.
Results
Patient characteristics
A total of 200 high-risk liver transplant recipients were
randomized to receive either fluconazole or anidulafungin
(100 patients per group). The two groups were similar in
terms of demographic characteristics and risk factors for
IFIs (Table 1). Approximately, 75% of the patients in each
group had a MELD 30, while 60% in each group required
renal replacement therapy. The median duration of
prophylaxis was 21 days for both fluconazole (range, 5–
43) and anidulafungin patients (range, 5–46). Thirty-six
fluconazole patients received<21 days of study drug due to
early discharge from the hospital (31 patients), early death
after transplantation (1 patient), development of an IFI (2
patients) or withdrawal of study drug by the primary
physician (2 patients). Similarly, 42 anidulafungin patients
received <21 days of study drug due to early discharge
from the hospital (37 patients), early death (2 patients),
development of an IFI (2 patients) or possible adverse event
related to study drug (1 patient).
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Efficacy
Two patients randomized to the anidulafungin group were
subsequently found to have invasive aspergillosis at time of
initiation of study drug and received<48h of anidulafungin.
Another patient randomized to fluconazole was withdrawn
on study day 1 by the primary physician and received less
than 24 h of fluconazole. These three patients were
excluded from the M-ITT population used for efficacy
analyses. As shown in Table 2, IFIs developed in 8% of
fluconazole and in 5.1%of anidulafungin patients (p¼ 0.40).
In the fluconazole group, there were six cases of invasive
candidiasis (all caused by nonalbicans Candida species) and
two cases of invasive aspergillosis. All the IFIs in the
anidulafungin group were due to Candida species. No
patients developed invasive aspergillosis on prophylactic
anidulafungin. Themedian time from initiation of study drug
to onset of IFI was longer in the anidulafungin group (43
days, range 7–87) compared to the fluconazole group (29
days, range 8–76), however this difference was not
statistically significant (p¼ 0.35). Breakthrough IFIs on
study drug occurred in two anidulafungin patients (2.0%)
and in five fluconazole patients (5.0%). Among patients
who had received a systemic antifungal agent prior to
transplantation (fluconazole in all cases), breakthrough IFIs
occurred in none of 14 anidulafungin patients but in 3 of 11
Table 1: Patient characteristics of intent-to-treat population
Characteristic1
Fluconazole
(N¼100)
Anidulafungin
(N¼100)
Median age (range), years 58 (27–74) 58 (19–75)
Gender
Male 72 (72%) 67 (67%)
Female 28 (28%) 33 (33%)
Primary liver disease2
Hepatitis C virus 39 (39%) 49 (49%)
Alcoholic cirrhosis 34 (34%) 37 (37%)
Primary sclerosing cholangitis 13 (13%) 9 (9%)
Primary biliary cirrhosis 3 (3%) 1 (1%)
Nonalcoholic steatohepatitis 2 (2%) 4 (4%)
Cryptogenic cirrhosis 9 (9%) 5 (5%)
Concomitant hepatocellular
carcinoma
20 (20%) 21 (21%)
Liver–kidney transplant 12 (12%) 11 (11%)
Cytomegalovirus seropositive
donor/seronegative recipient
14 (14%) 12 (12%)
Baseline immunosuppressive agents
Tacrolimus 95 (95%) 97 (97%)
Cyclosporine 5 (5%) 3 (3%)
Mycophenolate mofetil 93 (93%) 86 (86%)
Azathioprine 0 (0%) 1 (1%)
Prednisone 100 (100%) 97 (97%)
T cell depleting agent 7 (7%) 8 (8%)
Risk factors for invasive fungal infection
MELD 30 73 (73%) 76 (76%)
Renal replacement therapy 64 (64%) 58 (58%)
Fulminant hepatic failure 3 (3%) 2 (2%)
Corticosteroid therapy within
4 weeks of transplantation
2 (2%) 4 (4%)
Candida colonization at
2 sites pretransplantation
4 (4%) 3 (3%)
Intensive care stay >48h
pretransplantation
47 (47%) 34 (34%)
Receipt of systemic
antifungal agent within
30 days prior to
transplantation
12 (12%) 15 (15%)
Repeat liver transplant 12 (12%) 15 (15%)
Repeat abdominal surgery
during study
39 (39%) 37 (37%)
Blood loss >15U and
operative time >6 h
74 (74%) 67 (67%)
Number of patients with 1 or more risk factors3
1 18 (18%) 17 (17%)
2 17 (17%) 21 (21%)
3 20 (20%) 23 (23%)
4 18 (18%) 21 (21%)
>4 27 (27%) 19 (19%)
MELD, Model for End-Stage Liver Disease.
1None of the differences between study groups were statistically
significant (p>0.05) by chi-square test or rank sum test. For renal
replacement therapy, intensive care stay, and blood loss, p-values
were 0.35, 0.07, and 0.14, respectively.
2Some patients had more than one underlying liver disease.
3There was no significant difference between the study groups,
p¼0.756 by chi-square test.
Table 2: Incidence and types of invasive fungal infection in
modified intent-to-treat population1
Fungal infection or
pathogen
Fluconazole
(N¼99)
Anidulafungin
(N¼98) p-Value2
Invasive fungal infection 8 (8.0%) 5 (5.1%) 0.40
Invasive candidiasis3 6 (6.0%) 5 (5.1%) 0.75
Candidemia 4 4
Candida albicans 0 1
Candida glabrata 1 2
Candida tropicalis 1 1
Candida krusei 1 0
Candida dublinensis 1 0
Intraabdominal infection,
abscess, peritonitis
24 1
Candida albicans 0 1
Candida glabrata 1 0
Candida kefyr 1 0
Invasive aspergillosis3 2 (2.0%) 0 (0.0%) 0.49
Pulmonary 2 0
Aspergillus fumigatus 2 0
1Modified intent-to-treat population excludes one fluconazole
patient withdrawn on study day 1 by primary physician and two
anidulafungin patients found to have invasive aspergillosis at study
entry.
2p-Value from Cochran–Mantel–Haenszel test.
3Two C. glabrata infections, oneC. krusei fungemia and both cases
of invasive aspergillosis in the fluconazole group and one case each
of C. glabrata and C. albicans fungemia in the anidulafungin
group were breakthrough infections occurring during receipt of
study drug. Other fungal infections occurred after the study drug
administration period.
4One fluconazole patient had abdominal abscess with both
C. glabrata and C. kefyr.
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fluconazole patients (27.3%) (p¼0.07). There was no
significant difference in breakthrough IFIs among patients
not receiving a systemic antifungal agent prior to transplan-
tation (2 in 84 anidulafungin patients or 2.4% vs. 2 in 88
fluconazole patients or 2.3%, p¼ 0.96). The breakthrough
IFIs were treated with caspofungin alone (three patients),
voriconazole alone (one patient), micafungin plus flucona-
zole (two patients) and voriconazole plus caspofungin or
micafungin (one patient). None of these IFIs were fatal, and
there were no adverse effects of antifungal therapy.
IFIs in all patients were diagnosed on the basis of a culture
positive for a fungal pathogen and EORTC/MSG criteria.
Fungal isolates (Candida species 8, Aspergillus species 1)
from nine patients (fluconazole 6, anidulafungin 3) with IFIs
were available for susceptibility testing. All nine isolates
were sensitive to anidulafungin (minimum inhibitory
concentration [MIC] 0.25mg/mL). In contrast, five of
the eight Candida isolates were resistant to fluconazole
with MICs 16mg/mL. Of the six fluconazole-resistant
fungal isolates in study patients, five caused infection in
the fluconazole group and one caused infection in the
anidulafungin group. Three anidulafungin patients, who
developed candidemia after completing 42 days of
prophylactic anidulafungin, had Candida isolates still sensi-
tive to anidulafungin.
The risk for IFI with anidulafungin prophylaxis compared to
fluconazole prophylaxis by prespecified established risk
factors for IFI is summarized in Table 3. For all subgroups,
there were no significant differences in the overall risk
for IFI between anidulafungin patients and fluconazole
patients. However, for patients who had a MELD score
30, required renal replacement therapy, were given
>15U of packed red blood cells during transplant surgery,
or had received fluconazole before transplantation, there
was a lower risk for a breakthrough IFI with anidulafungin
prophylaxis.
Fungal colonization
Assessment of fungal colonization was based on results of
cultures of the oropharynx, respiratory secretions and urine
performed as part of standard patient care. Colonization
was documented in 38 of 99 fluconazole patients (38%) and
in 39 of 98 anidulafungin patients (39.7%; p¼ 0.93). The
incidence of Candida colonization was similar for the two
study groups; Candida albicans and Candida glabrata were
the predominant organisms associated with colonization in
each group. Colonization with Aspergillus was more
frequent in the fluconazole group (7 of 99 patients, 7%)
than the anidulafungin group (3 of 98 patients, 3%;
p¼ 0.18). All seven Aspergillus isolates associated with
colonization and available for antifungal susceptibility
testing were sensitive to anidulafungin (MIC0.125mg/
mL). The overall incidence of Aspergillus infection or
colonization was 9% (9 of 99 patients) in the fluconazole
and 3% (3 of 98 patients) in the anidulafungin group
(p¼0.08).
Safety
Primary immunosuppressive therapy included tacrolimus
in 96% of all patients. Fluconazole patients compared to
anidulafungin patients had significantly higher median
tacrolimus levels at week 1 (5.4 vs. 4.8mg/mL, p¼ 0.036)
and at week 2 (8.2 vs. 7.1mg/mL, p¼0.020) during the
study. Nonetheless, there were no significant differences
in renal function, neurological events or other adverse
events between fluconazole and anidulafungin patients.
Similarly, there were no significant differences in serum
creatinine and liver function tests between the two study
groups. Adverse events leading to discontinuation of the
Table 3: Odds of invasive fungal infection with anidulafungin prophylaxis compared to fluconazole prophylaxis in prespecified high-risk
groups1
Prespecified risk group (N¼number of patients)
Odds of any IFI2 with
anidulafungin compared to
fluconazole in specified risk
group, odds ratio [95% CI],
p-value
Odds of breakthrough IFI2
with anidulafungin compared to
fluconazole in specified risk
group, odds ratio [95% CI],
p-value
MELD 30 (N¼146) 0.34 [0.08–1.35], 0.11 0.00 [0.00–0.70], 0.023
Renal replacement therapy (N¼119) 0.45 [0.11–1.87], 0.26 0.00 [0.00–1.05], 0.0563
Fulminant hepatic failure (N¼5) No IFI No IFI
Pretransplant corticosteroids (N¼6) No IFI No IFI
Pretransplant Candida colonization (N¼7) One IFI No IFI
Pretransplant intensive care unit stay >48h (N¼79) 0.67 [0.15–2.92], 0.59 0.00 [0.00–1.99], 0.143
Pretransplant systemic antifungal agent (N¼25) 0.21 [0.02–2.70], 0.18 0.00 [0.00–0.87], 0.043
Repeat liver transplant (N¼25) 1.66 [0.12–22.52], 0.70 1.66 [0.12–22.52], 0.70
Repeat abdominal surgery (N¼75) 0.49 [0.80–2.88], 0.42 0.00 [0.00–1.96], 0.163
Blood loss>15U PRBC during transplant surgery (N¼142) 0.47 [0.12–1.91], 0.28 0.00 [0.00–0.85], 0.033
CI, confidence interval; IFI, invasive fungal infection; MELD, Model for End-Stage Liver Disease; PRBC, packed red blood cells.
1Mantel–Haenszel test.
2Any IFI within 90 days of starting study drug or breakthrough infection while receiving study drug.
3Exact CI not calculated due to no breakthrough IFI in the anidulafungin group; fixed effect correction added to estimate CI.
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study drug occurred in 1 (1%) of 98 patients in the
anidulafungin group (prolonged QT interval) and in none of
the 99 fluconazole patients (p¼0.99).
Other outcomes and mortality
The incidence of rejection within 90 days of transplantation
was similar in the fluconazole and anidulafungin groups (4%
vs. 6%, p¼0.51). Kaplan–Meier estimates of fungal-free
survival showed no significant difference between the
anidulafungin group (94.5%; 95% CI, 87.4–97.7) and the
fluconazole group (91.3%; 95% CI, 83.3–95.5, p¼ 0.93).
The overall mortality rate at 90 days after transplantation
was 12% in each study group. Causes of death in the study
groups are shown in Table 4. There were no deaths due to
an IFI.
Discussion
IFIs occur in 36–50% of high-risk liver transplant recipients
without any effective antifungal prophylaxis (14,22–24). In
the only previous randomized, double-blind trial of antifun-
gal prophylaxis in liver transplant patients almost two
decades ago, fluconazole compared to placebo significantly
reduced IFIs (2). Since this pivotal study, there have been
very few additional definitive clinical trials of antifungal
prophylaxis in liver transplant patients or other types of solid
organ transplant recipients. Similarly, despite the favorable
profile of the echinocandins for antifungal prophylaxis,
there have been no previous randomized, double-blind,
controlled studies of an echinocandin for prevention of IFIs
in organ transplant recipients or other types of complex
surgical patients.
In randomized trials involving oncology patients receiving
either a stem cell transplant or chemotherapy, both
micafungin and caspofungin were as effective as flucona-
zole or itraconazole for antifungal prophylaxis (25–27). We
also found that the overall incidence of IFIs in high-risk liver
transplant recipients was similar for patients receiving a
prophylactic echinocandin (anidulafungin) or fluconazole.
The incidence of IFIs in our patients receiving prophylactic
anidulafungin (5%) was similar to the incidence reported in
previous small, noncontrolled studies of echinocandin
prophylaxis in high-risk liver transplant recipients and close
to the 4% incidence used to calculate our study’s sample
size (8–10). However, despite the inclusion of many
extremely ill patients (MELD 30 in 75% of the patients)
with well-established risk factors for IFI in our study, the
incidence of IFI in patients receiving prophylactic flucona-
zole was 8% and lower than the expected incidence of
18%, which was based on existing data from studies done
more than a decade ago (14,22–24). Indeed, despite the
increasing acuity and sickness of patients currently
undergoing liver transplantation, both patient and graft
survival have improved due to advances in immunosup-
pression, patient management, and surgical experi-
ence (28). These factors may have contributed to the
lower than expected incidence of IFI in the fluconazole
patients. It is also possible that current risk factors for IFI in
liver transplant recipients may differ from those risk factors
previously identified in earlier studies. In two recent
multivariate analyses of risk factors in the MELD era of
liver transplantation, a MELD score 30 was found to be
the most influential factor for IFI (17,18). The incidence of
probable or proven IFI in these two studies were 28% and
24%, respectively.
Based on the incidence of IFI in our study (5.1% with
anidulafungin, 8% with fluconazole) involving very sick
liver transplant patients with established risk factors for
IFI, an extremely large sample size (1125 patients per
study group or 2250 total patients) would be needed to
demonstrate a statistically significant difference in the
incidence of IFI (29). As such, it is unlikely that such a large
randomized, double-blind trial comparing an echinocandin
with fluconazole for antifungal prophylaxis would be
feasible.
Anidulafungin is active against Aspergillus as well as
several fluconazole-resistant Candida species. The inci-
dence of Aspergillus infection or colonization was lower in
our patients receiving anidulafungin (3% vs. 9%, p¼ 0.08).
In addition, more Candida species causing invasive
candidiasis in our study were resistant to fluconazole
(five isolates) than to anidulafungin (none of the isolates).
There was a higher incidence of breakthrough IFIs among
fluconazole patients (27%) compared to anidulafungin
patients (no patients; p¼ 0.07) who had received flucona-
zole before transplantation. These data suggest that
anidulafungin may be more beneficial for antifungal
prophylaxis in patients at higher risk for Aspergillus
infection or who were treated with fluconazole before
transplantation.
Table 4: Incidence of rejection, liver graft loss and death in the
intent-to-treat population
Outcome
Fluconazole
(N¼ 100)
Anidulafungin
(N¼ 100) p-Value
Rejection 4 (4%) 6 (6%) 0.52
Liver graft loss 14 (14%) 13 (13%) 0.86
Death
Within 90 days of transplantation 12 (12%) 12 (12%) 1.00
During study drug administration
period
3 (3%) 4 (4%) 0.72
Causes of death
Hepatic artery thrombosis/infarcts 4 3
Bacterial sepsis 2 2
Liver graft failure 1 1
Recurrent hepatitis C 1 0
Graft-versus-host disease 1 0
Cardiac events 2 1
Multi-organ failure 0 2
Pneumonia 0 1
Pulmonary embolism 0 1
Intracranial hemorrhage 0 1
Bowel infarct 1 0
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The protocol for this study allowed continuation of study
drug for a maximum of 42 days. During administration of
study drug, there were significantly fewer breakthrough
IFI on prophylactic anidulafungin among patients with a
MELD 30 (p¼0.02), requiring renal replacement therapy
(p¼0.06), receiving more than 15U of packed red blood
cells during transplant surgery (p¼ 0.03), or treated with
fluconazole before transplantation (p¼ 0.04; Table 3).
However, three anidulafungin patients developed candide-
mia caused by Candida organisms still sensitive to
anidulafungin after completing 42 days of anidulafungin
prophylaxis. Thus, in clinical practice, prophylaxis with
anidulafungin or another effective antifungal agentwill likely
need to be continued for a longer period if the patient still
has persistent risk factors for IFIs.
Adverse events were similar with anidulafungin and
fluconazole. Both drugs were generally well-tolerated.
Fluconazole in liver transplant recipients increases serum
cyclosporine levels (2) and was associated with higher
serum tacrolimus levels in this study. However, there was
no increase in tacrolimus nephrotoxicity or neurotoxicity
with fluconazole. Neither fluconazole nor anidulafungin had
any apparent hepatotoxicity.
A recent meta-analysis found that antifungal prophylaxis in
liver transplant recipients does not affect overall mortality
despite a significant reduction of IFI as well as mortality
attributable to fungal infection (3). Since IFI frequently occur
in critically ill liver transplant recipients with underlying host
factors (graft dysfunction, surgical complications, multi-
organ failure) that also greatly influence survival, this finding
is not surprising. In our study, the overall mortality rate at
90 days after transplantation was low (12% in each study
group), and there were no deaths due to IFI. Frequent
protocol-driven diagnostic studies in patients with sus-
pected fungal infection and subsequent initiation of early
appropriate antifungal therapy in patients with documented
IFI may have contributed to the absence of fungal-related
mortality.
The decision to use antifungal prophylaxis needs to
consider the possible emergence of resistant organisms
and cost (30). An increase in Candida krusei and Candida
glabrata infections has been associated with the use of
prophylactic fluconazole in some studies (31,32). There has
also been an increasing number of reports of echinocandin-
resistant Candida infections (33). Consequently, antifungal
prophylaxis in transplant recipients is frequently targeted to
high-risk patients with established risk factors for IFI (6).
Similarly, the significantly higher cost of an echinocandin,
which must be given intravenously, needs to be balanced
against the lower cost of fluconazole, which has the
convenience of both oral and intravenous administration. A
prophylactic strategy currently recommended for stem cell
transplant recipients, in which fluconazole is given for initial
prophylaxis and an echinocandin or mold-active azole is
reserved for patients at risk for Aspergillus infections or
fluconazole-resistant Candida infections, may also be
the most cost-effective approach for liver transplant
recipients (34).
In conclusion, formost liver transplant recipients at high risk
for IFIs, anidulafungin and fluconazole have similar efficacy
for antifungal prophylaxis. Both anidulafungin and flucona-
zole are well-tolerated in liver transplant recipients.
Prophylaxis with anidulafunginmay be beneficial in patients
who are at high risk for invasiveAspergillus or have received
fluconazole prior to transplantation.
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